Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | KLK7 | P49862 | 4/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620104 | 1.00 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL1859575 | 1.00 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL12632045 | 1.00 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL12632044 | 0.93 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL12632048 | 0.93 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL12632047 | 0.93 | SYK (0.47) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL1867177 | 0.92 | SYK (0.48) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL12632041 | 0.92 | SYK (0.46) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL1861661 | 0.92 | SYK (0.46) | SYKCTSLATMKLK7KLK5 | |
| SCHEMBL3612200 | 0.90 | SYK (0.46) | SYKCTSLATMKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | SYK 3258/4885CTSL 76/4885ATM 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.